Sg3 Management, LLC Sage Therapeutics, Inc. Call Options Transaction History

Sg3 Management, LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	BUY	$32.2 - $43.61 $483,000 - $654,150	15,000 New	15,000 $572,000
Q4 2021 Feb 15, 2022	SELL	$37.06 - $47.11 $207,536 - $263,816	-5,600 Reduced 8.67%	59,000 $2.51 Million
Q1 2021 May 17, 2021	BUY	$70.65 - $96.76 $4.56 Million - $6.25 Million	64,600 New	64,600 $4.84 Million
Q1 2019 May 14, 2019	SELL	$89.33 - $163.65 $267,990 - $490,950	-3,000 Closed	0 $0
Q4 2018 Feb 12, 2019	BUY	$81.94 - $139.71 $245,820 - $419,130	3,000 New	3,000 $287,000

218

48.2M

854K

195K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $395M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.